Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.
HABP/VABP
ME1100
aminoglycosides
arbekacin
inhalation
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
21 09 2020
21 09 2020
Historique:
received:
19
12
2019
accepted:
03
07
2020
pubmed:
15
7
2020
medline:
22
6
2021
entrez:
15
7
2020
Statut:
epublish
Résumé
ME1100 (arbekacin inhalation solution) is an inhaled aminoglycoside that is being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were undertaken to evaluate ME1100 regimens for the treatment of patients with HABP/VABP. The data used included a population pharmacokinetic (PPK) 4-compartment model with 1st-order elimination, nonclinical PK-PD targets from one-compartment
Identifiants
pubmed: 32661000
pii: AAC.02367-19
doi: 10.1128/AAC.02367-19
pmc: PMC7508573
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Dibekacin
45ZFO9E525
arbekacin
G7V6SLI20L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
Lancet Infect Dis. 2013 Aug;13(8):665-71
pubmed: 23622939
Curr Opin Pharmacol. 2017 Oct;36:114-123
pubmed: 29096171
JAMA. 2013 Jan 16;309(3):249-56
pubmed: 23321763
Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3
pubmed: 2520314
Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S103-10
pubmed: 20597657
Curr Opin Pharmacol. 2017 Oct;36:107-113
pubmed: 29128853
Chest. 2002 Dec;122(6):2115-21
pubmed: 12475855
Antimicrob Agents Chemother. 1975 Jul;8(1):58-62
pubmed: 1164007
Infection. 2013 Apr;41(2):447-56
pubmed: 23355330
Anesthesiology. 2001 Apr;94(4):554-60
pubmed: 11379672
Clin Pharmacol. 2014 Sep 26;6:139-48
pubmed: 25298740
Infect Chemother. 2013 Mar;45(1):62-8
pubmed: 24265951
Infect Control Hosp Epidemiol. 2012 Mar;33(3):250-6
pubmed: 22314062
Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S120-5
pubmed: 20597661
Intensive Care Med. 2010 May;36(5):781-9
pubmed: 20232046
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Chest. 2001 Aug;120(2):555-61
pubmed: 11502658
Chest. 2017 Nov;152(5):930-942
pubmed: 28455128
Antimicrob Agents Chemother. 2001 Jan;45(1):13-22
pubmed: 11120938
Antimicrob Agents Chemother. 2014;58(2):885-91
pubmed: 24277021
J Infect Chemother. 2013 Feb;19(1):128-37
pubmed: 23263188
Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1249-56
pubmed: 10194173
Antimicrob Agents Chemother. 2006 Nov;50(11):3763-9
pubmed: 17065622
Am J Respir Crit Care Med. 2011 Nov 15;184(10):1133-9
pubmed: 21852541
Minerva Anestesiol. 2018 Jul;84(7):811-819
pubmed: 29239151
J Infect Dis. 2019 Apr 19;219(10):1536-1544
pubmed: 30649434
Antimicrob Agents Chemother. 2015;59(6):3263-70
pubmed: 25801559
Antimicrob Agents Chemother. 2019 Jul 25;63(8):
pubmed: 31182524
Nephron. 1976;16(1):31-41
pubmed: 1244564
Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7
pubmed: 16127078
Jpn J Antibiot. 1987 Feb;40(2):349-56
pubmed: 3648153
Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2621-9
pubmed: 22422274
Crit Care Med. 2003 May;31(5):1312-7
pubmed: 12771596
Crit Care Med. 2014 Jan;42(1):1-8
pubmed: 24105456
Semin Respir Crit Care Med. 2014 Aug;35(4):469-81
pubmed: 25111643
Crit Care Med. 2005 Oct;33(10):2184-93
pubmed: 16215368